Psychedelic medicine (New Rochelle, N.Y.)Oct 22, 2026

Effects of LSD and 2,5-Dimethoxy-4-Iodoamphetamine on Oral Opioid Use and Withdrawal Symptoms in Male Mice

Psychedelic Science Weekly Brief ↗PubMed ↗DOI ↗

Updated Oct 23, 2026

Abstract

Currently, there are three FDA-approved medications for opioid use disorder (OUD), all of which have limitations.

Existing OUD medications are not especially effective and may cause withdrawal in dependent individuals.
These medications require daily administration, which can be a barrier to treatment adherence.
Single administrations of psychedelics have been shown to produce lasting anti-addiction effects in both humans and laboratory animals.
Research on the therapeutic potential of psychedelics for OUD remains limited.

Simplified

There are currently three FDA-approved medications for opioid use disorder (OUD), but none of them are especially effective, some can precipitate withdrawal in dependent individuals, and all of them require daily administration. In the appropriate settings, single administrations of psychedelics can elicit persistent anti-addiction effects in humans and in laboratory animals, but very few studies have assessed the potential therapeutic utility of psychedelics in OUD.

Full Text

Full text is available at the source.

View Full Text ↗

Effects of LSD and 2,5-Dimethoxy-4-Iodoamphetamine on Oral Opioid Use and Withdrawal Symptoms in Male Mice

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the psychedelic science brief